SAM Post Award Notification - 10.3.2024 (Cerus).pdf
PDF 80 KB Posted
- Attached to
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
- Solicitation number
- 75A50124C00046
About this file
This document is a post-award notification for Contract Number 75A50124C00046, awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Cerus Corporation on 9/23/2024. The contract, valued at $248,591,407.65, is for licensing pathogen reduction technology (PRT) for red blood cell (RBC) components to reduce the risk of transfusion-transmitted infection. The contract has 16 line items and is for services under PSC code AN13 - Health R&D Services; Health care services; Experimental Development. The work will be performed in the United States, and the contract was not set-aside. The related federal contract opportunity was a Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) with Solicitation Number 75A50124C00046.
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Contract Number: Contract Number: 75A50124C00046
Awarded: 9/23/2024
Contracting Office ZIP Code: 20201
PSC: AN13 - Health R&D Services; Health care services; Experimental Development NAICS Code: 541714 - Research and Development in Biotechnology (except
Nanobiotechnology)
Contracting Office Address:
Constitution Center, 400 7th St SW Washington, D.C. 20024
Subject: Award Notice: 75A50124C00046
Solicitation Number: BAA-23-100-SOL-00004
Contracting Officer: Jonathan Gonzalez@hhs.gov
Total Contract Award Value (base and all options): $248,591,407.65
Line Item Number: CLIN 0001 – CLIN 0016
Contract Award Date: 9/23/2024
Contractor: Cerus Corporation
UEI: KJJQRRLY2FL5
Contractor Awarded Address: Concord, California 94520
Description: License pathogen reduction technology (PRT) for red blood cell (RBC) components to reduce the risk of transfusion-transmitted infection (TTI) by recognized emerging, epidemic, and endemic pathogens that is capable of treating over 10 million RBC components per year.
Place of Contract Performance: United States
Set-aside Status: N/A
File details come from the government source that posted it. Updated .